5CV.DE

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$85M	+45.0%	$-0.42	$-0.53–$-0.25	—	1
2027	$136M	+60.2%	$-0.09	$-0.11–$-0.05	—	1
2028	$174M	+27.6%	$-0.64	$-0.81–$-0.39	—	1
2029	$181M	+4.0%	$-0.55	$-0.69–$-0.33	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-08-15	$-0.18	$-0.26	-45.5%
2025-05-20	$-0.18	$-0.23	-26.5%
2025-04-10	$-0.21	$-0.15	+31.3%
2024-11-12	$1.41	$1.51	+7.1%
2024-08-15	$-0.28	$-0.32	-15.2%
2024-05-23	$-0.20	$-0.31	-58.1%
2023-11-14	$-0.23	$-0.22	+3.4%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
5CV.DECureVac N.V.	$3.91	+0.72%	$880M	—
2VSA.FVerastem, Inc.	$6.29	+1.65%	$553M	—
DRW3.DEDrägerwerk AG & Co. KGaA	$113.00	+0.53%	$2.1B	—
DRW8.DEDrägerwerk AG & Co. KGaA	$85.00	-1.39%	$2.1B	—
EUZ.DEEckert & Ziegler SE	$12.26	-0.73%

CureVac N.V.

CureVac N.V. is a biopharmaceutical entity operating in the clinical development phase, focused on pioneering revolutionary medicines utilizing messenger ribonucleic acid (mRNA) technology. Its portfolio includes prophylactic vaccines such as the mRNA-based candidate CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2. Another mRNA vaccine, CV7202, has successfully concluded Phase 1 trials for rabies, while CVSQIV is in Phase 1 development against influenza. The company is also advancing therapies for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Furthermore, CureVac is actively developing RNA-based immunotherapies for cancer, exemplified by CV8102, which is presently in Phase 1 clinical evaluation for cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancers affecting the skin, head, and neck. The company was established in 2000 and maintains its main office in Tübingen, Germany.

www.curevac.com

Employees: 825
IPO / List date: Aug 25, 2020
HQ: DE

Held by traders on TradeandTell

No one on the platform currently holds 5CV.DE.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 5CV.DE as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 5CV.DE yet.